Abridge wants to be the operating system for medicine—and NVIDIA and Eli Lilly are helping build it
Abridge, a startup focused on ambient AI for healthcare, has announced a significant expansion of its platform and secured new strategic investments. The company's AI-native clinician intelligence platform now aims to manage billing, clinical decision support, and pharmaceutical trial screening, building on its existing capabilities of documenting patient-clinician conversations. Abridge has raised approximately $1.1 billion to date, with its latest funding round including investment from NVIDIA's venture arm, NVentures, and pharmaceutical giant Eli Lilly. AI
IMPACT Accelerates AI integration into clinical workflows, potentially improving efficiency and patient outcomes across healthcare systems.